As on date of publishing, this report will capture the impact assessment of COVID-19 on this market and the same will be considered in our market forecast model. Clients purchasing this report between April and June 2020 will be getting a ‘free’ updated market data excel sheet between July and September 2020 accounting for the impact of COVID-19 on the market in the current year 2020 and forecast.

Global frontotemporal dementia market is poised to undergo a robust CAGR during the forecast period owing to the increasing cases of dementia across the globe. The rising number of geriatric populations is one of the major factors driving the growth of this market, as people above 65 years of age are more prone to this disorder. Further,  increasing funding by governments across the world for research and development activities to find the best treatment for neurological disorders such as dementia and Alzheimer’s are expected to support the growth of frontotemporal dementia market in the coming years.

Frontotemporal dementia refers to a group of disorders caused by progressive nerve cell loss in the brain's frontal lobes (the areas behind forehead) or its temporal lobes (the regions behind ears). The nerve cell damage caused by frontotemporal dementia leads to loss of necessary function in these brain regions, which variably cause deterioration in behavior and personality, language disturbances, or alterations in muscle or motor functions. There are higher chances of misunderstanding of frontotemporal disorder with Alzheimer’s disease, which is a serious concern and might hamper the growth of the market.

Global frontotemporal dementia market can be segmented based on drug class type, disease type, distribution channel, end user and region. Based on disease type, the market is segmented into Behavior Variant Frontotemporal Dementia (bvFTD), Primary Progressive Aphasia (PPA) and others. Among them, the behavior variant frontotemporal dementia segment is anticipated to grow substantially until 2025 owing to their rising prevalence around the world. Their symptoms include behavioral changes, apathy and changes in stereotypic behavior. Based on region, the global frontotemporal dementia market is led by North America in terms of revenue. The region has one of the finest healthcare facilities in the world, which is enabling manufacturers to operate seamlessly. Also, growing awareness about dementia and high per capita disposable income are acting as key growth drivers for frontotemporal dementia market in the region. 

Major companies operating in global frontotemporal dementia market include Pfizer Inc., Novartis AG, F. Hoffmann-La Roche Ltd., AstraZeneca GmbH, Sanofi S.A, Merck & Co., Inc., auRX Therapeutics, Alector Pharma Co., Valeant Pharmaceutical International, GlaxoSmithKline Plc., Allergen plc, Eli Lilly and Company, Johnson & Johnson and Mylan N.V., among others. The market is highly fragmented with some leading players dominating the global market. The companies are investing on latest technologies to offer more advanced drugs with reduced side-effects.

Years considered for this report:

Historical Years: 2015-2018

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2021–2025

Objective of the Study:

  • To analyze and forecast the market size of global frontotemporal dementia market.
  • To forecast global frontotemporal dementia market based on drug class type, disease type, distribution channel, end user, company and regional distribution.
  • To identify drivers and challenges for global frontotemporal dementia market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in global frontotemporal dementia market.
  • To identify and analyze the profile of leading players operating in the global frontotemporal dementia market.


Click here to download the sample

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of frontotemporal dementia companies across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the companies which could not be identified due to the limitations of secondary research.

TechSci Research calculated global frontotemporal dementia market size using a bottom-up approach, where data for various end user industries and its application across various product types were recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used by TechSci Research.


Key Target Audience:

  • Frontotemporal dementia drug manufacturers, companies, hospitals/clinics and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, industry associations, forums and alliances related to frontotemporal dementia
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as frontotemporal dementia drug manufacturing companies, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global frontotemporal dementia market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global Frontotemporal Dementia Market, By Drug Class Type:
    • Antidepressants
      • Fluoxetine
      • Fluvoxamine
      • Sertraline
      • Paroxetine
      • Citalopram
      • Bupropion
      • Mitrazepine
    • Antipsychotics
      • Olanzepine
      • Quetiapine
      • Ziprasidone
      • Aripiprazole
      • Risperidone
      • Paliperidone
  • Global Frontotemporal Dementia Market, By Disease Type:
    • Behavior Variant Frontotemporal Dementia (bvFTD)
    • Primary Progressive Aphasia (PPA)
    • Others
  • Global Frontotemporal Dementia Market, By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Drug Store
    • Online Pharmacy
    • Others
  • Global Frontotemporal Dementia Market, By End User:
    • Hospitals
    • Specialty Clinics
    • Others
  • Global Frontotemporal Dementia Market, By Region:
    • Asia-Pacific
      • China
      • Japan
      • India 
      • South Korea
      • Australia
      • Singapore
    • Europe
      • France
      • Germany
      • United Kingdom
      • Italy
      • Spain
    • North America
      • United States
      • Mexico
      • Canada
    • South America
      • Brazil
      • Colombia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global frontotemporal dementia market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Profit Margin Analysis

  • Profit margin analysis in case of direct and indirect sales channel.
It is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com  

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com

1.    Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on Global Frontotemporal Dementia Market

4.    Executive Summary

5.    Voice of Customer

6.    Global Frontotemporal Dementia Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Drug Class Type (Antidepressants (Fluoxetine, Fluvoxamine, Sertraline, Paroxetine, Citalopram, Bupropion, Mitrazepine), Antipsychotics (Olanzepine, Quetiapine, Ziprasidone, Aripiprazole, Risperidone, Paliperidone)

6.2.2.     By Disease Type (Behavior Variant Frontotemporal Dementia (bvFTD), Primary Progressive Aphasia (PPA), Others)

6.2.3.     By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Drug Store, Online Pharmacy, Others)

6.2.4.     By End User (Hospitals, Specialty Clinics, Others)

6.2.5.     By Company (2019)

6.2.6.     By Region

6.3.  Market Attractiveness Index

7.    Asia-Pacific Frontotemporal Dementia Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Drug Class Type

7.2.2.     By Disease Type

7.2.3.     By Distribution Channel

7.2.4.     By End User

7.2.5.     By Country

7.3.  Market Attractiveness Index

7.4.  Asia-Pacific: Country Analysis

7.4.1.     China Frontotemporal Dementia Market Outlook

7.4.1.1.         Market Size & Forecast

7.4.1.1.1.             By Value

7.4.1.2.         Market Share & Forecast

7.4.1.2.1.             By Drug Class Type

7.4.1.2.2.             By Disease Type

7.4.1.2.3.             By Distribution Channel

7.4.1.2.4.             By End User

7.4.2.     India Frontotemporal Dementia Market Outlook

7.4.2.1.         Market Size & Forecast

7.4.2.1.1.             By Value

7.4.2.2.         Market Share & Forecast

7.4.2.2.1.             By Drug Class Type

7.4.2.2.2.             By Disease Type

7.4.2.2.3.             By Distribution Channel

7.4.2.2.4.             By End User

7.4.3.     Japan Frontotemporal Dementia Market Outlook

7.4.3.1.         Market Size & Forecast

7.4.3.1.1.             By Value

7.4.3.2.         Market Share & Forecast

7.4.3.2.1.             By Drug Class Type

7.4.3.2.2.             By Disease Type

7.4.3.2.3.             By Distribution Channel

7.4.3.2.4.             By End User

7.4.4.     South Korea Frontotemporal Dementia Market Outlook

7.4.4.1.         Market Size & Forecast

7.4.4.1.1.             By Value

7.4.4.2.         Market Share & Forecast

7.4.4.2.1.             By Drug Class Type

7.4.4.2.2.             By Disease Type

7.4.4.2.3.             By Distribution Channel

7.4.4.2.4.             By End User

7.4.5.     Singapore Frontotemporal Dementia Market Outlook

7.4.5.1.         Market Size & Forecast

7.4.5.1.1.             By Value

7.4.5.2.         Market Share & Forecast

7.4.5.2.1.             By Drug Class Type

7.4.5.2.2.             By Disease Type

7.4.5.2.3.             By Distribution Channel

7.4.5.2.4.             By End User

7.4.6.     Australia Frontotemporal Dementia Market Outlook

7.4.6.1.         Market Size & Forecast

7.4.6.1.1.             By Value

7.4.6.2.         Market Share & Forecast

7.4.6.2.1.             By Drug Class Type

7.4.6.2.2.             By Disease Type

7.4.6.2.3.             By Distribution Channel

7.4.6.2.4.             By End User

8.    Europe Frontotemporal Dementia Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Drug Class Type

8.2.2.     By Disease Type

8.2.3.     By Distribution Channel

8.2.4.     By End User

8.2.5.     By Country

8.3.  Market Attractiveness Index

8.4.  Europe: Country Analysis

8.4.1.     France Frontotemporal Dementia Market Outlook

8.4.1.1.         Market Size & Forecast

8.4.1.1.1.             By Value

8.4.1.2.         Market Share & Forecast

8.4.1.2.1.             By Drug Class Type

8.4.1.2.2.             By Disease Type

8.4.1.2.3.             By Distribution Channel

8.4.1.2.4.             By End User

8.4.2.     Germany Frontotemporal Dementia Market Outlook

8.4.2.1.         Market Size & Forecast

8.4.2.1.1.             By Value

8.4.2.2.         Market Share & Forecast

8.4.2.2.1.             By Drug Class Type

8.4.2.2.2.             By Disease Type

8.4.2.2.3.             By Distribution Channel

8.4.2.2.4.             By End User

8.4.3.     United Kingdom Frontotemporal Dementia Market Outlook

8.4.3.1.         Market Size & Forecast

8.4.3.1.1.             By Value

8.4.3.2.         Market Share & Forecast

8.4.3.2.1.             By Drug Class Type

8.4.3.2.2.             By Disease Type

8.4.3.2.3.             By Distribution Channel

8.4.3.2.4.             By End User

8.4.4.     Italy Frontotemporal Dementia Market Outlook

8.4.4.1.         Market Size & Forecast

8.4.4.1.1.             By Value

8.4.4.2.         Market Share & Forecast

8.4.4.2.1.             By Drug Class Type

8.4.4.2.2.             By Disease Type

8.4.4.2.3.             By Distribution Channel

8.4.4.2.4.             By End User

8.4.5.     Spain Frontotemporal Dementia Market Outlook

8.4.5.1.         Market Size & Forecast

8.4.5.1.1.             By Value

8.4.5.2.         Market Share & Forecast

8.4.5.2.1.             By Drug Class Type

8.4.5.2.2.             By Disease Type

8.4.5.2.3.             By Distribution Channel

8.4.5.2.4.             By End User

9.    North America Frontotemporal Dementia Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Drug Class Type

9.2.2.     By Disease Type

9.2.3.     By Distribution Channel

9.2.4.     By End User

9.2.5.     By Country

9.3.  Market Attractiveness Index

9.4.  North America: Country Analysis

9.4.1.     United States Frontotemporal Dementia Market Outlook

9.4.1.1.         Market Size & Forecast

9.4.1.1.1.             By Value

9.4.1.2.         Market Share & Forecast

9.4.1.2.1.             By Drug Class Type

9.4.1.2.2.             By Disease Type

9.4.1.2.3.             By Distribution Channel

9.4.1.2.4.             By End User

9.4.2.     Mexico Frontotemporal Dementia Market Outlook

9.4.2.1.         Market Size & Forecast

9.4.2.1.1.             By Value

9.4.2.2.         Market Share & Forecast

9.4.2.2.1.             By Drug Class Type

9.4.2.2.2.             By Disease Type

9.4.2.2.3.             By Distribution Channel

9.4.2.2.4.             By End User

9.4.3.     Canada Frontotemporal Dementia Market Outlook

9.4.3.1.         Market Size & Forecast

9.4.3.1.1.             By Value

9.4.3.2.         Market Share & Forecast

9.4.3.2.1.             By Drug Class Type

9.4.3.2.2.             By Disease Type

9.4.3.2.3.             By Distribution Channel

9.4.3.2.4.             By End User

10.  South America Frontotemporal Dementia Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Drug Class Type

10.2.2.  By Disease Type

10.2.3.  By Distribution Channel

10.2.4.  By End User

10.2.5.  By Country

10.3.              Market Attractiveness Index

10.4.              South America: Country Analysis

10.4.1.  Brazil Frontotemporal Dementia Market Outlook

10.4.1.1.      Market Size & Forecast

10.4.1.1.1.           By Value

10.4.1.2.      Market Share & Forecast

10.4.1.2.1.           By Drug Class Type

10.4.1.2.2.           By Disease Type

10.4.1.2.3.           By Distribution Channel

10.4.1.2.4.           By End User

10.4.2.  Argentina Frontotemporal Dementia Market Outlook

10.4.2.1.      Market Size & Forecast

10.4.2.1.1.           By Value

10.4.2.2.      Market Share & Forecast

10.4.2.2.1.           By Drug Class Type

10.4.2.2.2.           By Disease Type

10.4.2.2.3.           By Distribution Channel

10.4.2.2.4.           By End User

10.4.3.  Colombia Frontotemporal Dementia Market Outlook

10.4.3.1.      Market Size & Forecast

10.4.3.1.1.           By Value

10.4.3.2.      Market Share & Forecast

10.4.3.2.1.           By Drug Class Type

10.4.3.2.2.           By Disease Type

10.4.3.2.3.           By Distribution Channel

10.4.3.2.4.           By End User

11.  Middle East and Africa Frontotemporal Dementia Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Drug Class Type

11.2.2.  By Disease Type

11.2.3.  By Distribution Channel

11.2.4.  By End User

11.2.5.  By Country

11.3.              Market Attractiveness Index

11.4.              MEA: Country Analysis

11.4.1.  South Africa Frontotemporal Dementia Market Outlook

11.4.1.1.      Market Size & Forecast

11.4.1.1.1.